Concussion, MildRACENCT05588115
Rapid, Accurate, Cost-effective Assessment of Blood Biomarkers for Diagnosis of Concussion
An observational study of Concussion, Mild, run by University of Calgary at 1 site in Canada.
Trial summary
The goal of this observational study is to test if a biosensor can accurately measure a blood biomarker in adult patients presenting to the emergency department with concussion. The main questions it aims to answer are: Does the biosensor measure the blood biomarker of interest with the same accuracy as the current… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Concussion, Mild
- How many people
- 225 participants
- Where
- 1 siteCanada
- Study dates
- 1 Dec 2022to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: For the exposure of interest group, adult patients (ages 18 to 65) with an uncomplicated concussion diagnosis at Foothills Medical Centre Emergency Department in Calgary Alberta will be approached to participate in this study regardless of race, ethnicity, or gender. For the control group, adult patients (ages 18 to 65) with a musculoskeletal (MSK) injury (fractured bone, connective tissue damage, etc.) at Foothills Medical Centre Emergency Department in Calgary Alberta will be approached to participate in this study regardless of race, ethnicity, or gender.
Who may be able to join
- diagnosed with an uncomplicated concussion according to the ICD-10 criteria with no intracranial abnormalities
- between the ages of 18-65 years old.
- diagnosed with any form of musculoskeletal injury in absence of comorbidities
- between the ages of 18-65 years old
Who cannot join
- complicated mild TBI (positive neuroimaging findings)
- current or history of moderate or severe traumatic brain injury
- history of neurological issue(s) (stroke, seizures, dementia, Alzheimer's, etc.) or metabolic disease(s) (diabetes, liver disease, kidney disease, cardiovascular disease, etc.)
- greater than 7 days from injury at initial visit
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Foothills Medical Centre
Calgary, Alberta, T2N 2T9
Bianca M Perry, MSc, 4039448643, bianca.perry@ucalgary.ca
Christina Campbell, MSc, (403)944-8643, Christina.Campbell@albertahealthservices.ca
About this study
Official title: RACE Study: Rapid, Accurate and Cost-effective Analysis of Glial Fibrillary Acid Protein Using a Hand-held Biosensor for Patient With Concussion in Acute Care and at Home Monitoring
The goal of this observational study is to test if a biosensor can accurately measure a blood biomarker in adult patients presenting to the emergency department with concussion. The main questions it aims to answer are:
- Does the biosensor measure the blood biomarker of interest with the same accuracy as the current gold-standard assay technique?
- Do relationships exist between blood biomarker measurements from the biosensor and any psychological or physical symptoms of concussion?
Read more
Participants will be asked to provide blood samples at initial visit and 2-, 6-, and 12-weeks after injury while completing questionnaires at each visit, along with a brief (2 min) daily symptom inventory.
Researchers will compare the concussion group to a muscle/skeletal injury group to see if measurements from the biosensor are exclusive to concussion.
Read the detailed description
BACKGROUND
It is estimated 100-300/100,000 people worldwide present to a hospital with traumatic brain injury (TBI) annually, the majority of which are classified as mild. TBI is a disruption in normal brain function caused by external biomechanical forces transmitted directly or indirectly to the head, and is a leading cause of death and disability in Canada. Approximately 1 in 450 Canadians report brain injury as their most significant injury associated with disability in the previous year. Mild traumatic brain injury (mTBI) is operationalized under clinical severity by a Glasgow Coma Scale (GCS) score of 13-15 and is often used interchangeably with concussion, though the most recent consensus definition of concussion is precluded by positive findings on standard neuroimaging techniques. Although labelled as mild with typical recovery times within two weeks of injury for adults and four weeks for youth, up to 30% of patients with concussion experience prolonged symptoms (headache, fatigue, dizziness, insomnia, depression, anxiety, poor balance, and cognitive deficits, etc.) contributing to significant functional impairment and disease burden. Furthermore, in 2016 approximately 10% of diagnosed concussions in Ontario returned to the emergency department within 14 days of injury, increasing demands on the health care system.
Lending to its identity as one of the most complex injuries to diagnose and manage, concussion currently relies on subjective measures and symptom reports as clinical indices of injury. There has been accelerated interest in addressing this limitation through research efforts working to establish objective measures of injury including advanced neuroimaging imaging techniques, machine learning of basic physiological functions (brain waves, heart rate, blood pressure, etc.), and blood biomarkers. Blood biomarkers have shown promising results regarding their ability to detect or predict severe and moderate TBI, but results in mTBI are mixed and require further investigation. Two biomarkers of brain injury - glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase L1 (UCH-L1) - were recently FDA approved to help identify necessity of a CT scan for adult mTBI patients who might have intracranial lesions. However, beyond the currently insufficient level of evidence regarding blood biomarker applications for concussion diagnosis or prognosis, an additional hurdle for future implementation in a clinical setting remains the high cost and time-consuming assay methodologies for marker detection. Single molecule array technology (SIMOA) is a fully automated immunoassay capable of biomarker detection at the femtogram level, approximately 900x more sensitive than conventional enzyme-linked immunosorbent assays. As the current gold-standard for low concentration biomarker detection, significant monetary and procedural costs may limit SIMOA's future applications for concussion biomarker detection in clinical settings. Fortunately, technological advancements are pushing the boundaries of conventional assay approaches to minimize cost and maximize efficiency, progressing towards point-of-care assay devices.
The investigators have developed a GFAP nano-biosensor capable of measuring GFAP concentrations in similar orders of magnitude as SIMOA. Briefly, the GFAP electrochemical biosensor was developed using nano-porous carbon on screen-printed electrodes with hydroxylamine (NH2OH). The nano-coated and functionalized electrodes were immobilized with monoclonal anti-human GFAP capture antibody, then blocked with bovine serum albumin. GFAP binding frequency was translated to serum concentration levels using electrochemical impedance spectroscopy (EIS). The nano-porous biosensor provided ultrasensitive GFAP detection in a wide operational range of 100 fg/mL - 10 ng/mL concentrations in the human serum. It selectively detected GFAP when tested against other biomarkers released after brain injury, and revealed a clinical sensitivity for detection of patients across TBI severities (total n=70; TBI n=26, healthy control n=44) at 84.62% (95%CI, 65.1% to 95.6%) and specificity at 61.36% (CI, 45.5% to 75.6%). The limit of detection of the GFAP biosensor was measured to be 86.6 fg/mL in serum. Additionally, our nano-biosensor demonstrated <2% intra-variation and <1% inter-variation, tackling the concern of reproducible biosensor production needed for clinical detection. This research seeks to validate the nano-biosensor in concussion patients presenting to the Emergency Department.
OBJECTIVES
Primary Aim: Establish the clinical accuracy of the GFAP nano-biosensor in patients with concussion presenting to the emergency department from diagnosis to recovery. Secondary Aim: Assess sensitivity and specificity of the GFAP nano-biosensor for identification of concussion by comparing concussion patients to musculoskeletal (MSK) injury controls. Tertiary Aim: Assess relationships between GFAP nano-biosensor concentrations and psychological (depression, anxiety), physical (headache, sleep disturbances, etc.) symptoms of concussion from diagnosis to recovery. Quaternary aim: Assess correlation between female menstrual cycle hormone concentrations (progesterone, estrogen) and GFAP nano-biosensor concentrations.
METHODS
This study has a recruitment target of 150 (equal sex representation) acute concussion patients presenting to the emergency department (ED) at foothills medical centre ages 18 through 65. Additionally, a group of 75 (equal sex representation) musculoskeletal (MSK) injury controls will be recruited from the same ED within the same age range. In a repeated measures prospective cohort design, concussion patients will complete an initial visit within 1 week of injury, then follow-up visits at 2-, 6-, and 12-weeks post-injury or until recovered. Control (MSK) patients will complete all measures at a single visit. Concussion patients who are not recovered by 12 weeks post-injury will be asked to complete questionnaires at 6 months post-injury. Study measures include clinical outcome assessments of quality of life, global health, depression, anxiety, sleep, and concussion symptoms, along with blood draws. Concussion patients will be asked to complete the post concussion symptom scale (PCSS) daily via an online link sent to them each morning to monitor recovery. For the purposes of this study, a patient will be deemed recovered if all symptoms have resolved and indicating 100% on a sliding scale that asks how recovered the patient feels from the concussion. All other questionnaires will be completed prior to initial and follow-up blood draws. Researchers will also be providing concussion patients with a QR code linked to the investigators website where patients will have access to concussion education resources to understand the injury. The two assay techniques will be compared using mean detection and distribution curves and Bland-Altman analysis. The performance of the GFAP biosensing kit in detection of uncomplicated concussion patients and monitoring their recovery will be assessed in plasma and serum. The clinical sensitivity and specificity of the GFAP biosensor in plasma and serum will be evaluated using the receiver operating characteristic (ROC) curve in comparison to SIMOA.
- Conditions
- Concussion, Mild
- Keywords
- blood biomarkers, GFAP, biosensor, concussion
- Medical subject headings
- Brain Concussion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Concussion | Patients presenting to the ED who are diagnosed with concussion according to the ICD-10 criteria and absent of comorbidities. | |
| MSK | Patients presenting to the ED who are diagnosed with a muscle or skeletal injury (MSK; soft tissue damage or inflammation, fractured bone, etc.) and absent of comorbidities. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood serum concentrations of GFAP at initial visit
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: Up to 1 week following injury
Blood serum concentrations of GFAP at 2 week follow up
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: 2-3 weeks following injury
Blood serum concentrations of GFAP at 6 week follow up
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: 6-7 weeks following injury
Blood serum concentrations of GFAP at 12 week follow up
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: 12-13 weeks following injury
Blood plasma concentrations of GFAP at initial visit
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: Up to 1 week following injury
Blood plasma concentrations of GFAP at 2 week follow up
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: 2-3 weeks following injury
Blood plasma concentrations of GFAP at 6 week follow up
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: 6-7 weeks following injury
Blood plasma concentrations of GFAP at 12 week follow up
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Measured: 12-13 weeks following injury
Secondary outcomes (36)
Glasgow Outcome Scale Extended (GOSE)
Assesses outcomes following brain injury. Scores range from 1 to 8 with higher scores meaning better outcomes.
Measured: Up to 1 week following injury
Glasgow Outcome Scale Extended (GOSE)
Assesses outcomes following brain injury. Scores range from 1 to 8 with higher scores meaning better outcomes.
Measured: 2-3 weeks following injury
Glasgow Outcome Scale Extended (GOSE)
Assesses outcomes following brain injury. Scores range from 1 to 8 with higher scores meaning better outcomes.
Measured: 6-7 weeks following injury
Glasgow Outcome Scale Extended (GOSE)
Assesses outcomes following brain injury. Scores range from 1 to 8 with higher scores meaning better outcomes.
Measured: 12-13 weeks following injury
Glasgow Outcome Scale Extended (GOSE)
Assesses outcomes following brain injury. Scores range from 1 to 8 with higher scores meaning better outcomes.
Measured: 24-25 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Assesses general quality of life. Health state scores (not on a scale) and a visual analog scale from 0-100 with higher scores meaning better outcomes.
Measured: Up to 1 week following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Assesses general quality of life. Health state scores (not on a scale) and a visual analog scale from 0-100 with higher scores meaning better outcomes.
Measured: 2-3 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Assesses general quality of life. Health state scores (not on a scale) and a visual analog scale from 0-100 with higher scores meaning better outcomes.
Measured: 6-7 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Assesses general quality of life. Health state scores (not on a scale) and a visual analog scale from 0-100 with higher scores meaning better outcomes.
Measured: 12-13 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Assesses general quality of life. Health state scores (not on a scale) and a visual analog scale from 0-100 with higher scores meaning better outcomes.
Measured: 24-25 weeks following injury
PROMIS Global health
Assesses mental and physical health. Scores are provided on both domains from 0 to 20 with higher scores meaning better outcomes.
Measured: Up to 1 week following injury
PROMIS Global health
Assesses mental and physical health. Scores are provided on both domains from 0 to 20 with higher scores meaning better outcomes.
Measured: 2-3 weeks following injury
PROMIS Global health
Assesses mental and physical health. Scores are provided on both domains from 0 to 20 with higher scores meaning better outcomes.
Measured: 6-7 weeks following injury
PROMIS Global health
Assesses mental and physical health. Scores are provided on both domains from 0 to 20 with higher scores meaning better outcomes.
Measured: 12-13 weeks following injury
PROMIS Global health
Assesses mental and physical health. Scores are provided on both domains from 0 to 20 with higher scores meaning better outcomes.
Measured: 24-25 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Assesses feelings of depression. Scores range from 0 to 27 with higher scores meaning worse outcomes.
Measured: Up to 1 week following injury
Patient Health Questionnaire 9 (PHQ-9)
Assesses feelings of depression. Scores range from 0 to 27 with higher scores meaning worse outcomes.
Measured: 2-3 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Assesses feelings of depression. Scores range from 0 to 27 with higher scores meaning worse outcomes.
Measured: 6-7 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Assesses feelings of depression. Scores range from 0 to 27 with higher scores meaning worse outcomes.
Measured: 12-13 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Assesses feelings of depression. Scores range from 0 to 27 with higher scores meaning worse outcomes.
Measured: 24-25 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Assesses feelings of anxiety. Scores range from 0 to 15 with higher scores meaning worse outcomes.
Measured: Up to 1 week following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Assesses feelings of anxiety. Scores range from 0 to 15 with higher scores meaning worse outcomes.
Measured: 2-3 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Assesses feelings of anxiety. Scores range from 0 to 15 with higher scores meaning worse outcomes.
Measured: 6-7 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Assesses feelings of anxiety. Scores range from 0 to 15 with higher scores meaning worse outcomes.
Measured: 12-13 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Assesses feelings of anxiety. Scores range from 0 to 15 with higher scores meaning worse outcomes.
Measured: 24-25 weeks following injury
Life Event Checklist 5 (LEC-5)
Assesses exposure to potentially stressful life events. Not a scale.
Measured: Up to 1 week following injury
Sleep and Concussion Questionnaire
Assesses sleep disturbances following concussion. Not a scale.
Measured: Up to 1 week following injury
Sleep and Concussion Questionnaire
Assesses sleep disturbances following concussion. Not a scale.
Measured: 2-3 weeks following injury
Sleep and Concussion Questionnaire
Assesses sleep disturbances following concussion. Not a scale.
Measured: 6-7 weeks following injury
Sleep and Concussion Questionnaire
Assesses sleep disturbances following concussion. Not a scale.
Measured: 12-13 weeks following injury
Sleep and Concussion Questionnaire
Assesses sleep disturbances following concussion. Not a scale.
Measured: 24-25 weeks following injury
Pre-blood draw questionnaire
Assesses factors that may influence blood GFAP concentrations (i.e., exercise, drugs, COVID-19, etc.). Not a scale.
Measured: Up to 1 week following injury
Pre-blood draw questionnaire
Assesses factors that may influence blood GFAP concentrations (i.e., exercise, drugs, COVID-19, etc.). Not a scale.
Measured: 2-3 weeks following injury
Pre-blood draw questionnaire
Assesses factors that may influence blood GFAP concentrations (i.e., exercise, drugs, COVID-19, etc.). Not a scale.
Measured: 6-7 weeks following injury
Pre-blood draw questionnaire
Assesses factors that may influence blood GFAP concentrations (i.e., exercise, drugs, COVID-19, etc.). Not a scale.
Measured: 12-13 weeks following injury
Post Concussion Symptom Scale (PCSS)
Assesses symptoms of concussion. Scores given for total number of symptoms (0-22) and symptom severity (0-132) with
Measured: Through study completion, on average of 2-3 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2022
- Study start1 Dec 2022
- Primary completion30 Apr 2025
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for Concussion, MildStudies of the same condition, open and under way.
- More trials run by University of CalgaryThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 225 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Calgary
- Sponsor type
- University, hospital or other
- Collaborators
- Foothills Medical Centre
- Responsible party
- Sponsor
- Investigators
- Chantel T Debert, MD, MSc, Principal investigator, University of Calgary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05588115
- Sponsor's protocol ID
- REB22-1015
- Acronym
- RACE
- Status last verified
- Jan 2026
- First submitted
- 4 Oct 2022
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cassidy JD, Carroll LJ, Peloso PM, Borg J, von Holst H, Holm L, Kraus J, Coronado VG; WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. 2004 Feb;(43 Suppl):28-60. doi: 10.1080/16501960410023732.
PubMed 15083870Najem D, Rennie K, Ribecco-Lutkiewicz M, Ly D, Haukenfrers J, Liu Q, Nzau M, Fraser DD, Bani-Yaghoub M. Traumatic brain injury: classification, models, and markers. Biochem Cell Biol. 2018 Aug;96(4):391-406. doi: 10.1139/bcb-2016-0160. Epub 2018 Jan 25.
PubMed 29370536Gordon KE, Kuhle S. Canadians Reporting Sport-Related Concussions: Increasing and Now Stabilizing. Clin J Sport Med. 2022 May 1;32(3):313-317. doi: 10.1097/JSM.0000000000000888. Epub 2020 Sep 17.
PubMed 32956100Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974 Jul 13;2(7872):81-4. doi: 10.1016/s0140-6736(74)91639-0. No abstract available.
PubMed 4136544McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, Cantu RC, Cassidy D, Echemendia RJ, Castellani RJ, Davis GA, Ellenbogen R, Emery C, Engebretsen L, Feddermann-Demont N, Giza CC, Guskiewicz KM, Herring S, Iverson GL, Johnston KM, Kissick J, Kutcher J, Leddy JJ, Maddocks D, Makdissi M, Manley GT, McCrea M, Meehan WP, Nagahiro S, Patricios J, Putukian M, Schneider KJ, Sills A, Tator CH, Turner M, Vos PE. Consensus statement on concussion in sport-the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017 Jun;51(11):838-847. doi: 10.1136/bjsports-2017-097699. Epub 2017 Apr 26. No abstract available.
PubMed 28446457McMahon P, Hricik A, Yue JK, Puccio AM, Inoue T, Lingsma HF, Beers SR, Gordon WA, Valadka AB, Manley GT, Okonkwo DO; TRACK-TBI Investigators. Symptomatology and functional outcome in mild traumatic brain injury: results from the prospective TRACK-TBI study. J Neurotrauma. 2014 Jan 1;31(1):26-33. doi: 10.1089/neu.2013.2984. Epub 2013 Oct 31.
PubMed 23952719Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur J Neurol. 2003 Sep;10(5):471-7. doi: 10.1046/j.1468-1331.2003.00682.x.
PubMed 12940825Morrison L, Taylor R, Mercuri M, Thompson J. Examining Canada's return visits to the emergency department after a concussion. CJEM. 2019 Nov;21(6):784-788. doi: 10.1017/cem.2019.22.
PubMed 30947758McCrea M, Meier T, Huber D, Ptito A, Bigler E, Debert CT, Manley G, Menon D, Chen JK, Wall R, Schneider KJ, McAllister T. Role of advanced neuroimaging, fluid biomarkers and genetic testing in the assessment of sport-related concussion: a systematic review. Br J Sports Med. 2017 Jun;51(12):919-929. doi: 10.1136/bjsports-2016-097447. Epub 2017 Apr 28.
PubMed 28455364Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
PubMed 27068280Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 2016 Oct;12(10):563-74. doi: 10.1038/nrneurol.2016.127. Epub 2016 Sep 16.
PubMed 27632903Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, Gunnar Brolinson P, Buki A, Chen JY, Christenson RH, Hack D, Huff JS, Johar S, Jordan JD, Leidel BA, Lindner T, Ludington E, Okonkwo DO, Ornato J, Peacock WF, Schmidt K, Tyndall JA, Vossough A, Jagoda AS. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 2018 Sep;17(9):782-789. doi: 10.1016/S1474-4422(18)30231-X. Epub 2018 Jul 24.
PubMed 30054151Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, Liman V, Norgren N, Blennow K, Zetterberg H. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. doi: 10.1515/cclm-2015-1195.
PubMed 27071153
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- RACE Study: Rapid, Accurate and Cost-effective Analysis of Glial Fibrillary Acid Protein Using a Hand-held Biosensor for Patient With Concussion in Acute Care and at Home Monitoring
- ClinicalTrials.gov ID
- NCT05588115
- Acronym / sponsor ID
- RACE / REB22-1015
- Conditions
- Concussion, Mild
- Keywords
- blood biomarkers, GFAP, biosensor, concussion
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 225 participants (estimated)
- Lead sponsor
- University of CalgaryUniversity, hospital or other
- Collaborators
- Foothills Medical Centre
- Study start
- 1 Dec 2022 (actual)
- Primary completion
- 30 Apr 2025 (actual)
- Study completion
- Dec 2027 (estimated)
- First posted
- 20 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to test if a biosensor can accurately measure a blood biomarker in adult patients presenting to the emergency department with concussion. The main questions it aims to answer are:
- Does the biosensor measure the blood biomarker of interest with the same accuracy as the current gold-standard assay technique?
- Do relationships exist between blood biomarker measurements from the biosensor and any psychological or physical symptoms of concussion?
Participants will be asked to provide blood samples at initial visit and 2-, 6-, and 12-weeks after injury while completing questionnaires at each visit, along with a brief (2 min) daily symptom inventory.
Researchers will compare the concussion group to a muscle/skeletal injury group to see if measurements from the biosensor are exclusive to concussion.
Detailed description
BACKGROUND
It is estimated 100-300/100,000 people worldwide present to a hospital with traumatic brain injury (TBI) annually, the majority of which are classified as mild. TBI is a disruption in normal brain function caused by external biomechanical forces transmitted directly or indirectly to the head, and is a leading cause of death and disability in Canada. Approximately 1 in 450 Canadians report brain injury as their most significant injury associated with disability in the previous year. Mild traumatic brain injury (mTBI) is operationalized under clinical severity by a Glasgow Coma Scale (GCS) score of 13-15 and is often used interchangeably with concussion, though the most recent consensus definition of concussion is precluded by positive findings on standard neuroimaging techniques. Although labelled as mild with typical recovery times within two weeks of injury for adults and four weeks for youth, up to 30% of patients with concussion experience prolonged symptoms (headache, fatigue, dizziness, insomnia, depression, anxiety, poor balance, and cognitive deficits, etc.) contributing to significant functional impairment and disease burden. Furthermore, in 2016 approximately 10% of diagnosed concussions in Ontario returned to the emergency department within 14 days of injury, increasing demands on the health care system.
Lending to its identity as one of the most complex injuries to diagnose and manage, concussion currently relies on subjective measures and symptom reports as clinical indices of injury. There has been accelerated interest in addressing this limitation through research efforts working to establish objective measures of injury including advanced neuroimaging imaging techniques, machine learning of basic physiological functions (brain waves, heart rate, blood pressure, etc.), and blood biomarkers. Blood biomarkers have shown promising results regarding their ability to detect or predict severe and moderate TBI, but results in mTBI are mixed and require further investigation. Two biomarkers of brain injury - glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase L1 (UCH-L1) - were recently FDA approved to help identify necessity of a CT scan for adult mTBI patients who might have intracranial lesions. However, beyond the currently insufficient level of evidence regarding blood biomarker applications for concussion diagnosis or prognosis, an additional hurdle for future implementation in a clinical setting remains the high cost and time-consuming assay methodologies for marker detection. Single molecule array technology (SIMOA) is a fully automated immunoassay capable of biomarker detection at the femtogram level, approximately 900x more sensitive than conventional enzyme-linked immunosorbent assays. As the current gold-standard for low concentration biomarker detection, significant monetary and procedural costs may limit SIMOA's future applications for concussion biomarker detection in clinical settings. Fortunately, technological advancements are pushing the boundaries of conventional assay approaches to minimize cost and maximize efficiency, progressing towards point-of-care assay devices.
The investigators have developed a GFAP nano-biosensor capable of measuring GFAP concentrations in similar orders of magnitude as SIMOA. Briefly, the GFAP electrochemical biosensor was developed using nano-porous carbon on screen-printed electrodes with hydroxylamine (NH2OH). The nano-coated and functionalized electrodes were immobilized with monoclonal anti-human GFAP capture antibody, then blocked with bovine serum albumin. GFAP binding frequency was translated to serum concentration levels using electrochemical impedance spectroscopy (EIS). The nano-porous biosensor provided ultrasensitive GFAP detection in a wide operational range of 100 fg/mL - 10 ng/mL concentrations in the human serum. It selectively detected GFAP when tested against other biomarkers released after brain injury, and revealed a clinical sensitivity for detection of patients across TBI severities (total n=70; TBI n=26, healthy control n=44) at 84.62% (95%CI, 65.1% to 95.6%) and specificity at 61.36% (CI, 45.5% to 75.6%). The limit of detection of the GFAP biosensor was measured to be 86.6 fg/mL in serum. Additionally, our nano-biosensor demonstrated <2% intra-variation and <1% inter-variation, tackling the concern of reproducible biosensor production needed for clinical detection. This research seeks to validate the nano-biosensor in concussion patients presenting to the Emergency Department.
OBJECTIVES
Primary Aim: Establish the clinical accuracy of the GFAP nano-biosensor in patients with concussion presenting to the emergency department from diagnosis to recovery. Secondary Aim: Assess sensitivity and specificity of the GFAP nano-biosensor for identification of concussion by comparing concussion patients to musculoskeletal (MSK) injury controls. Tertiary Aim: Assess relationships between GFAP nano-biosensor concentrations and psychological (depression, anxiety), physical (headache, sleep disturbances, etc.) symptoms of concussion from diagnosis to recovery. Quaternary aim: Assess correlation between female menstrual cycle hormone concentrations (progesterone, estrogen) and GFAP nano-biosensor concentrations.
METHODS
This study has a recruitment target of 150 (equal sex representation) acute concussion patients presenting to the emergency department (ED) at foothills medical centre ages 18 through 65. Additionally, a group of 75 (equal sex representation) musculoskeletal (MSK) injury controls will be recruited from the same ED within the same age range. In a repeated measures prospective cohort design, concussion patients will complete an initial visit within 1 week of injury, then follow-up visits at 2-, 6-, and 12-weeks post-injury or until recovered. Control (MSK) patients will complete all measures at a single visit. Concussion patients who are not recovered by 12 weeks post-injury will be asked to complete questionnaires at 6 months post-injury. Study measures include clinical outcome assessments of quality of life, global health, depression, anxiety, sleep, and concussion symptoms, along with blood draws. Concussion patients will be asked to complete the post concussion symptom scale (PCSS) daily via an online link sent to them each morning to monitor recovery. For the purposes of this study, a patient will be deemed recovered if all symptoms have resolved and indicating 100% on a sliding scale that asks how recovered the patient feels from the concussion. All other questionnaires will be completed prior to initial and follow-up blood draws. Researchers will also be providing concussion patients with a QR code linked to the investigators website where patients will have access to concussion education resources to understand the injury. The two assay techniques will be compared using mean detection and distribution curves and Bland-Altman analysis. The performance of the GFAP biosensing kit in detection of uncomplicated concussion patients and monitoring their recovery will be assessed in plasma and serum. The clinical sensitivity and specificity of the GFAP biosensor in plasma and serum will be evaluated using the receiver operating characteristic (ROC) curve in comparison to SIMOA.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Concussion | – | –Patients presenting to the ED who are diagnosed with concussion according to the ICD-10 criteria and absent of comorbidities. |
| MSK | – | –Patients presenting to the ED who are diagnosed with a muscle or skeletal injury (MSK; soft tissue damage or inflammation, fractured bone, etc.) and absent of comorbidities. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- For the exposure of interest group, adult patients (ages 18 to 65) with an uncomplicated concussion diagnosis at Foothills Medical Centre Emergency Department in Calgary Alberta will be approached to participate in this study regardless of race, ethnicity, or gender. For the control group, adult patients (ages 18 to 65) with a musculoskeletal (MSK) injury (fractured bone, connective tissue damage, etc.) at Foothills Medical Centre Emergency Department in Calgary Alberta will be approached to participate in this study regardless of race, ethnicity, or gender.
Key inclusion criteria (4 listed)
- diagnosed with an uncomplicated concussion according to the ICD-10 criteria with no intracranial abnormalities
- between the ages of 18-65 years old.
- diagnosed with any form of musculoskeletal injury in absence of comorbidities
- between the ages of 18-65 years old
Key exclusion criteria (4 listed)
- complicated mild TBI (positive neuroimaging findings)
- current or history of moderate or severe traumatic brain injury
- history of neurological issue(s) (stroke, seizures, dementia, Alzheimer's, etc.) or metabolic disease(s) (diabetes, liver disease, kidney disease, cardiovascular disease, etc.)
- greater than 7 days from injury at initial visit
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Blood serum concentrations of GFAP at initial visit
Time frame: Up to 1 week following injury
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Blood serum concentrations of GFAP at 2 week follow up
Time frame: 2-3 weeks following injury
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Blood serum concentrations of GFAP at 6 week follow up
Time frame: 6-7 weeks following injury
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Blood serum concentrations of GFAP at 12 week follow up
Time frame: 12-13 weeks following injury
Compare serum concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Blood plasma concentrations of GFAP at initial visit
Time frame: Up to 1 week following injury
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Blood plasma concentrations of GFAP at 2 week follow up
Time frame: 2-3 weeks following injury
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Blood plasma concentrations of GFAP at 6 week follow up
Time frame: 6-7 weeks following injury
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
Blood plasma concentrations of GFAP at 12 week follow up
Time frame: 12-13 weeks following injury
Compare plasma concentrations of GFAP measured by the biosensor and the current gold-standard SIMOA technology.
36 secondary outcomes
Glasgow Outcome Scale Extended (GOSE)
Time frame: Up to 1 week following injury
Glasgow Outcome Scale Extended (GOSE)
Time frame: 2-3 weeks following injury
Glasgow Outcome Scale Extended (GOSE)
Time frame: 6-7 weeks following injury
Glasgow Outcome Scale Extended (GOSE)
Time frame: 12-13 weeks following injury
Glasgow Outcome Scale Extended (GOSE)
Time frame: 24-25 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Time frame: Up to 1 week following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Time frame: 2-3 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Time frame: 6-7 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Time frame: 12-13 weeks following injury
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L)
Time frame: 24-25 weeks following injury
PROMIS Global health
Time frame: Up to 1 week following injury
PROMIS Global health
Time frame: 2-3 weeks following injury
PROMIS Global health
Time frame: 6-7 weeks following injury
PROMIS Global health
Time frame: 12-13 weeks following injury
PROMIS Global health
Time frame: 24-25 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Time frame: Up to 1 week following injury
Patient Health Questionnaire 9 (PHQ-9)
Time frame: 2-3 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Time frame: 6-7 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Time frame: 12-13 weeks following injury
Patient Health Questionnaire 9 (PHQ-9)
Time frame: 24-25 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Time frame: Up to 1 week following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Time frame: 2-3 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Time frame: 6-7 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Time frame: 12-13 weeks following injury
Generalized Anxiety Disorder Questionnaire 7 (GAD-7)
Time frame: 24-25 weeks following injury
Life Event Checklist 5 (LEC-5)
Time frame: Up to 1 week following injury
Sleep and Concussion Questionnaire
Time frame: Up to 1 week following injury
Sleep and Concussion Questionnaire
Time frame: 2-3 weeks following injury
Sleep and Concussion Questionnaire
Time frame: 6-7 weeks following injury
Sleep and Concussion Questionnaire
Time frame: 12-13 weeks following injury
Sleep and Concussion Questionnaire
Time frame: 24-25 weeks following injury
Pre-blood draw questionnaire
Time frame: Up to 1 week following injury
Pre-blood draw questionnaire
Time frame: 2-3 weeks following injury
Pre-blood draw questionnaire
Time frame: 6-7 weeks following injury
Pre-blood draw questionnaire
Time frame: 12-13 weeks following injury
Post Concussion Symptom Scale (PCSS)
Time frame: Through study completion, on average of 2-3 weeks.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Background: PubMed 15083870Cassidy JD, Carroll LJ, Peloso PM, Borg J, von Holst H, Holm L, Kraus J, Coronado VG; WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. 2004 Feb;(43 Suppl):28-60. doi: 10.1080/16501960410023732.
- Background: PubMed 29370536Najem D, Rennie K, Ribecco-Lutkiewicz M, Ly D, Haukenfrers J, Liu Q, Nzau M, Fraser DD, Bani-Yaghoub M. Traumatic brain injury: classification, models, and markers. Biochem Cell Biol. 2018 Aug;96(4):391-406. doi: 10.1139/bcb-2016-0160. Epub 2018 Jan 25.
- Background: PubMed 32956100Gordon KE, Kuhle S. Canadians Reporting Sport-Related Concussions: Increasing and Now Stabilizing. Clin J Sport Med. 2022 May 1;32(3):313-317. doi: 10.1097/JSM.0000000000000888. Epub 2020 Sep 17.
- Background: PubMed 4136544Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974 Jul 13;2(7872):81-4. doi: 10.1016/s0140-6736(74)91639-0. No abstract available.
- Background: PubMed 28446457McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, Cantu RC, Cassidy D, Echemendia RJ, Castellani RJ, Davis GA, Ellenbogen R, Emery C, Engebretsen L, Feddermann-Demont N, Giza CC, Guskiewicz KM, Herring S, Iverson GL, Johnston KM, Kissick J, Kutcher J, Leddy JJ, Maddocks D, Makdissi M, Manley GT, McCrea M, Meehan WP, Nagahiro S, Patricios J, Putukian M, Schneider KJ, Sills A, Tator CH, Turner M, Vos PE. Consensus statement on concussion in sport-the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017 Jun;51(11):838-847. doi: 10.1136/bjsports-2017-097699. Epub 2017 Apr 26. No abstract available.
- Background: PubMed 23952719McMahon P, Hricik A, Yue JK, Puccio AM, Inoue T, Lingsma HF, Beers SR, Gordon WA, Valadka AB, Manley GT, Okonkwo DO; TRACK-TBI Investigators. Symptomatology and functional outcome in mild traumatic brain injury: results from the prospective TRACK-TBI study. J Neurotrauma. 2014 Jan 1;31(1):26-33. doi: 10.1089/neu.2013.2984. Epub 2013 Oct 31.
- Background: PubMed 12940825Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur J Neurol. 2003 Sep;10(5):471-7. doi: 10.1046/j.1468-1331.2003.00682.x.
- Background: PubMed 30947758Morrison L, Taylor R, Mercuri M, Thompson J. Examining Canada's return visits to the emergency department after a concussion. CJEM. 2019 Nov;21(6):784-788. doi: 10.1017/cem.2019.22.
- Background: PubMed 28455364McCrea M, Meier T, Huber D, Ptito A, Bigler E, Debert CT, Manley G, Menon D, Chen JK, Wall R, Schneider KJ, McAllister T. Role of advanced neuroimaging, fluid biomarkers and genetic testing in the assessment of sport-related concussion: a systematic review. Br J Sports Med. 2017 Jun;51(12):919-929. doi: 10.1136/bjsports-2016-097447. Epub 2017 Apr 28.
- Background: PubMed 27068280Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
- Background: PubMed 27632903Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 2016 Oct;12(10):563-74. doi: 10.1038/nrneurol.2016.127. Epub 2016 Sep 16.
- Background: PubMed 30054151Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, Gunnar Brolinson P, Buki A, Chen JY, Christenson RH, Hack D, Huff JS, Johar S, Jordan JD, Leidel BA, Lindner T, Ludington E, Okonkwo DO, Ornato J, Peacock WF, Schmidt K, Tyndall JA, Vossough A, Jagoda AS. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 2018 Sep;17(9):782-789. doi: 10.1016/S1474-4422(18)30231-X. Epub 2018 Jul 24.
- Individual participant dataSharing planned: No
Related trials for Concussion, Mild
Enrolling by invitationPhase 1
Pilot Safety and Exploratory Efficacy of PSC-05 for the Treatment of Chronic Mild Traumatic Brain Injury
Mild Traumatic Brain Injury
Recruiting
Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)
Sleep Architecture, Mild Traumatic Brain Injury
Active, not recruiting
Pilot TMS in Mild TBI
Persistent Post Concussive Headache, Mild Traumatic Brain Injury
Recruiting
Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline
Mild Traumatic Brain Injury, Post Concussion Syndrome
Enrolling by invitation
Improving In-hospital and Post-discharge Patient Education for Mild Traumatic Brain Injury
Concussion, Mild, Traumatic Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chantel T Debert, MD, MSc principal investigator
University of Calgary
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Concussion, Mild, run by University of Calgary at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chantel T Debert, MD, MSc (4039444500, cdebert@ucalgary.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood serum concentrations of GFAP at initial visit (time frame: Up to 1 week following injury). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05588115, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.